Drug Trial Radar · NCT05464030
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
220
Actual
Start
Aug 4, 2022
Primary completion
Oct 23, 2026
Study completion Oct 23, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jul 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program
Conditions
- Colorectal Cancer
Interventions
M9140Drug
M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.
M9140Drug
M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.
BevacizumabDrug
Bevacizumab will be administered intravenously as per standard of care.
CapecitabineDrug
Capecitabine will be administered orally as per standard of care.
5-fluorouracil (5-FU)Drug
5-FU will be administered intravenously as per standard of care.
Folinic acidDrug
Folinic acid will be administered intravenously as per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)Time frame: up to 4 months
- Part 1: Recommended Dose Expansion (RDE) of M9140Time frame: up to 4 months
- Parts 2B, 2C and 2D: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)Time frame: up to 8 months
- Part 2A: Number of Participants with Adverse Events (AEs)Time frame: up to 8 months
- Part 2A: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months
- Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment to planned assessment at approximately 8 months
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California
California Cancer Associates for Research & Excellence, Inc.
Fresno, California
Rhode Island Hospital
Providence, Rhode Island
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center - Oncology
Houston, Texas
NEXT Oncology
San Antonio, Texas
The Ottawa Hospital Cancer Centre
Ottawa, Canada
University Health Network - Princess Margaret Cancer Centre
Toronto, Canada
National Cancer Center Hospital - Dept of Gastroenterology
Chūōku, Japan
National Cancer Center Hospital East
Kashiwa-shi, Japan
Saitama Cancer Center
Kitaadachi-gun, Japan
Cancer Institute Hospital of JFCR
Kōtoku, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
Kindai University Hospital
Osakasayama-shi, Japan
Shizuoka Cancer Center
Sunto-gun, Japan
Kanagawa Cancer Center
Yokohama, Japan
Kyungpook National University Chilgok Hospital
Daegu, South Korea
National Cancer Center
Goyang-si, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Hospital HM Nou Delfos
Barcelona, Spain
Hospital Universitari Vall d'Hebron - VHIR
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Quironsalud Madrid - NEXT Oncology
Madrid, Spain
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.